Goldman Sachs’s Sagimet Biosciences SGMT Stock Holding History

Goldman Sachs’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$884K	Buy	169,259 +43,313	+34%	+$241K	﹤0.01%	5176
2025 Q4	$746K	Buy	125,946 +110,754	+729%	+$796K	﹤0.01%	5343
2025 Q3	$104K	Sell	15,192 -3,429	-18%	-$27.8K	﹤0.01%	6071
2025 Q2	$142K	Sell	18,621 -4,982	-21%	-$21K	﹤0.01%	5750
2025 Q1	$76.9K	Sell	23,603 -109,464	-82%	-$459K	﹤0.01%	5831
2024 Q4	$599K	Buy	133,067 +348	+0.3%	+$1.76K	﹤0.01%	5138
2024 Q3	$368K	Sell	132,719 -129,369	-49%	-$399K	﹤0.01%	5208
2024 Q2	$896K	Buy	262,088 +232,342	+781%	+$1.07M	﹤0.01%	4480
2024 Q1	$161K	Buy	+29,746	New	+$214K	﹤0.01%	5168
2023 Q4	–	Sell	-19,654	Closed	-$173K	–	5817
2023 Q3	$173K	Buy	+19,654	New	+$262K	﹤0.01%	5077

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's SGMT Position: Q1 2026 in Review

Goldman Sachs increased its Sagimet Biosciences (SGMT) stake by 34% in Q1 2026, buying an estimated $241K and bringing the position to 169,259 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #5176.

Goldman Sachs first reported a position in SGMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $896K in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

Goldman Sachs held 169,259 shares of Sagimet Biosciences worth $884K as of Q1 2026.
Goldman Sachs bought 43,313 Sagimet Biosciences shares in Q1 2026, an estimated $241K.
Sagimet Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5176 holding.
Goldman Sachs first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 10 quarters since.
Goldman Sachs's Sagimet Biosciences position peaked at $896K in Q2 2024.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.